Acasti Pharma Inc

For the period ended Dec 31, 2023. Filed Feb 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2023 · Filed Feb 12, 2024

GRCE$1.86-0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

	Three months ended		Nine months ended
	December 31,2023	December 31,2022	December 31,2023	December 31,2022
(Expressed in thousands, except share and per share data)	$	$	$	$
Operating expenses
Research and development expenses, net of government assistance	(1,443)	(2,450)	(2,998)	(8,332)
General and administrative expenses	(1,570)	(1,589)	(4,922)	(5,187)
Sales and marketing	(30)	(206)	(184)	(563)
Restructuring cost	—	—	(1,485)	—
Loss from operating activities	(3,043)	(4,245)	(9,589)	(14,082)
Foreign exchange gain (loss)	3	15	(2)	(75)
Change in fair value of derivative warrant liabilities	125	—	(1,701)	10
Interest income and other expense, net	316	67	662	134
Total other income (expense), net	444	82	(1,041)	69
Loss before income tax recovery	(2,599)	(4,163)	(10,630)	(14,013)
Income tax recovery	208	274	943	671
Net loss and total comprehensive loss	(2,391)	(3,889)	(9,687)	(13,342)
Basic and diluted loss per share	(0.21)	(0.52)	(1.09)	(1.80)
Weighted-average number of shares outstanding	11,506,257	7,435,472	8,874,872	7,416,318

See accompanying notes to unaudited interim consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.